Akari Therapeutics (AKTX) Other Non Operating Income (2014 - 2026)
Akari Therapeutics recorded quarterly Other Non Operating Income of $64000.0 in Q1 2026, up 149.23% quarter-over-quarter from -$130000.0 in Q4 2025, and up 151.2% year-over-year from $25477.7 in Q1 2025.
Akari Therapeutics' Other Non Operating Income history runs 13 years deep, the most recent figure standing at $64000.0 for Q1 2026.
- In Q1 2026, Other Non Operating Income rose 151.2% year-over-year to $64000.0; the TTM figure through Mar 2026 stood at -$1.1 million (up 96.13% YoY), while the FY2025 annual figure was -$230000.0, down 3933.33% from the prior year.
- Other Non Operating Income came in at $64000.0 for Q1 2026 at Akari Therapeutics, up from -$130000.0 in the prior quarter.
- In the past five years, Other Non Operating Income ranged from a high of $208000.0 in Q4 2023 to a low of -$28.0 million in Q4 2024.
- A 5-year average of -$1.9 million and a median of -$11000.0 in 2023 frame the typical range for Other Non Operating Income.
- Across the five-year window, Other Non Operating Income jumped 1208.86% in 2022 and sank 13564.9% in 2024, its largest moves.
- Akari Therapeutics' Other Non Operating Income stood at $141424.0 in 2022, then soared by 47.08% to $208000.0 in 2023, then tumbled by 13564.9% to -$28.0 million in 2024, then soared by 99.54% to -$130000.0 in 2025, then surged by 149.23% to $64000.0 in 2026.
- According to Business Quant data, Other Non Operating Income over the past three periods registered $64000.0, -$130000.0, and -$967000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Revolution Medicines | 32.39 Bn | 32.39 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 64,000.00 |
| Dec 31, 2025 | -130,000.00 |
| Sep 30, 2025 | -100,000.00 |
| Jun 30, 2025 | -50,000.00 |
| Mar 31, 2025 | -125,000.00 |
| Dec 31, 2024 | -28.01 Mn |
| Sep 30, 2024 | 68,000.00 |
| Jun 30, 2024 | 91,000.00 |
| Mar 31, 2024 | -2,000.00 |
| Dec 31, 2023 | 182,000.00 |
| Sep 30, 2023 | -100,000.00 |
| Jun 30, 2023 | -13,000.00 |
| Mar 31, 2023 | -11,000.00 |
| Jun 30, 2022 | 141,424.00 |
| Mar 31, 2022 | -82,362.00 |
| Dec 31, 2021 | -193.29 Bn |
| Sep 30, 2021 | 14,224.00 |
| Jun 30, 2021 | -12,754.00 |
| Mar 31, 2021 | 265,484.00 |
| Dec 31, 2020 | 488.53 Bn |
| Sep 30, 2020 | 156,360.00 |
| Jun 30, 2020 | 27,992.00 |
| Mar 31, 2020 | 233,404.00 |
| Dec 31, 2019 | 4,733.00 |
| Sep 30, 2019 | 37,209.00 |
| Jun 30, 2019 | 86,438.00 |
| Mar 31, 2019 | -195,635.00 |
| Dec 31, 2018 | 39,020.00 |
| Sep 30, 2018 | 36,036.00 |
| Jun 30, 2018 | 47,421.00 |
| Mar 31, 2018 | -37,816.00 |
| Dec 31, 2017 | -127,213.00 |
| Sep 30, 2017 | -218,274.00 |
| Jun 30, 2017 | 6,293.00 |
| Mar 31, 2017 | -38,785.00 |
| Dec 31, 2016 | -71,392.00 |
| Sep 30, 2016 | 102,737.00 |
| Jun 30, 2016 | 87,210.00 |
| Mar 31, 2016 | 154,431.00 |
| Dec 31, 2015 | -30,007.00 |
| Sep 30, 2015 | -22.00 |
| Jun 30, 2015 | -22.00 |
| Mar 31, 2015 | -37,601.00 |
| Dec 31, 2014 | -10,789.00 |
| Sep 30, 2014 | -2,218.00 |
| Jun 30, 2014 | 101,000.00 |
| Mar 31, 2014 | 143,000.00 |